SMART-C: 12 trials, 3000 on GLP1 - effects of SGLT2 consistent irrespective of GLP1

AMPLITUDE+HARMONY: 1200 on SGLT2 - effects of GLP1 consistent regardless of SGLT2

FLOW detailed SGLT2i data anticipated

All suggests independent effects and supports combo Rx

#ERA24 ERA - European Renal Association

I think ERA - European Renal Association this year is easily beating American Society of Nephrology #KidneyWk for most simultaneous publications at #ERA24

Let’s see

1/

all in - FLOW
Es ist eine große Freude und Ehre für uns, wenige Stunden nach der Publikation auf #ERA2024 und im NEJM mit Professor Mann die #FLOW Studie zu diskutieren.
Akademische Partner: @dgfn @oegn @sfndt

youtu.be/_wqIW9NGNL4?si… via YouTube

#SELECT Kidney Outcomes now out in Nature Medicine with #ERA24 !

Sema 2.4mg ow
✅ 22% ⬇️ 5-point kidney composite outcome, driven by UACR reduction
✅ 0.75mL/min slowing in eGFR decline

Kidney protection evident even in lower risk pts without DM or CKD!

nature.com/articles/s4159…

Original Article: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) nej.md/44U3slP

ERA - European Renal Association | #Nephrology #ERA24

Presented at #ERA24 :

In this phase 2 randomized trial, the CD38 monoclonal antibody felzartamab showed acceptable safety and promising efficacy among patients with chronic antibody-mediated kidney-transplant rejection. Read the full trial results: nej.md/4dHQhsa

Presented at #ERA24 :

Antinephrin autoantibodies occur in adults with minimal change disease and children with idiopathic nephrotic syndrome and appear to be disease activity markers. Their binding at slit diaphragms may induce podocyte dysfunction. nej.md/3UU5o9u

Simultaneous publication in JASN_News during Efficacy and safety of avenciguat in diabetic and non-diabetic kidney disease: Pooled analysis from two Phase II randomized controlled clinical trials

✍️By Hiddo Heerspink

🎨Simultaneous visual abstract publication (by

Rituximab – Belimumab in lupus nephritis by Y.K.Onno Teng
#ERA24

🌟Promising combination

🌟Targets surge of BAFF and memory B cells

🌟CALIBRATE and BEAT-LUPUS study👇👇